Stock Events

Stock Events

Intensity Therapeutics 

$4.06
49
+$0.05+1.37% 15:26 Today

Statistics

Day High
4.11
Day Low
3.99
52W High
43.5
52W Low
3.51
Volume
2,888
Avg. Volume
42,736
Mkt Cap
13.24M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.58
-1.1
-0.61
-0.13
Expected EPS
-0.986
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-11.61MNet Income

Analyst Ratings

7.00Average Price Target
The highest estimate is 7.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow INTS. It's not an investment recommendation.
Microsoft
4
MSFT
NVIDIA
4
NVDA
Apple
3
AAPL
Alphabet
3
GOOG

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. develops oncology drugs that directly compete with Intensity Therapeutics' cancer treatments.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb is involved in developing similar immuno-oncology drugs, competing in the same therapeutic areas as Intensity Therapeutics.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. has a broad portfolio of cancer drugs that overlaps with the treatments offered by Intensity Therapeutics.
Novartis
NVS
Mkt Cap292.35B
Novartis AG focuses on innovative cancer therapies, directly competing with Intensity Therapeutics in research and market presence.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company develops therapies for various cancers, competing with Intensity Therapeutics in terms of cancer treatment solutions.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. has a strong focus on oncology, particularly in therapies where Intensity Therapeutics is also active.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. competes in the oncology sector, offering advanced cancer treatments that rival those of Intensity Therapeutics.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC has a significant presence in the oncology market, developing drugs that compete with Intensity Therapeutics' products.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is known for its innovative biotechnology products in oncology, competing with Intensity Therapeutics.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division, develops cancer therapies that compete with Intensity Therapeutics' offerings.

About

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Show more...
CEO
Lewis H. Bender
Employees
7
Country
United States
ISIN
US45828J2024

Listings

BOATS
BOATS
INTS.BOATS
XNAS
US
INTS

0 Comments

Share your thoughts

FAQ

What is Intensity Therapeutics stock price today?▼
The current price of INTS is $4.06 USD — it has increased by +1.37% in the past 24 hours. Watch Intensity Therapeutics stock price performance more closely on the chart.
What is Intensity Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Intensity Therapeutics stocks are traded under the ticker INTS.
Is Intensity Therapeutics stock price growing?▼
INTS stock has fallen by -5.52% compared to the previous week, the month change is a -3.94% fall, over the last year Intensity Therapeutics has showed a -41.59% decrease.
What is Intensity Therapeutics market cap?▼
Today Intensity Therapeutics has the market capitalization of 13.24M
When is the next Intensity Therapeutics earnings date?▼
Intensity Therapeutics is going to release the next earnings report on November 17, 2026.
What were Intensity Therapeutics earnings last quarter?▼
INTS earnings for the last quarter are -1.11 USD per share, whereas the estimation was -0.87 USD resulting in a -27.22% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Intensity Therapeutics revenue for the last year?▼
Intensity Therapeutics revenue for the last year amounts to 0 USD.
What is Intensity Therapeutics net income for the last year?▼
INTS net income for the last year is -11.61M USD.
How many employees does Intensity Therapeutics have?▼
As of September 04, 2026, the company has 7 employees.
In which sector is Intensity Therapeutics located?▼
Intensity Therapeutics operates in the Health & Wellness sector.
When did Intensity Therapeutics complete a stock split?▼
The last stock split for Intensity Therapeutics was on February 19, 2026 with a ratio of 1:25.
Where is Intensity Therapeutics headquartered?▼
Intensity Therapeutics is headquartered in SHELTON, United States.